Contents

Current Clinical Pharmacology, Volume 6 - Number 3

Editorial [Hot Topic: Kidney Cancer: State of the Art in 2011 (Guest Editor: Ulka Vaishampayan)]

, 6(3): 143

Ulka Vaishampayan


DOI: 10.2174/157488411797189370




Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma

, 6(3): 144 - 150

Michel Choueiri, Nizar Tannir and Eric Jonasch


DOI: 10.2174/157488411797189415




Immunotherapy of Kidney Cancer

, 6(3): 151 - 163

Petros D. Grivas and Bruce G. Redman


DOI: 10.2174/157488411797189406




VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives

, 6(3): 164 - 168

Toni K. Choueiri


DOI: 10.2174/157488411797189424




Therapy for Non-Clear Cell Histologies in Renal Cancer

, 6(3): 169 - 180

Rhonda L. Bitting, John Madden and Andrew J. Armstrong


DOI: 10.2174/157488411797189460




Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma

, 6(3): 181 - 188

Priti Patel and Sandy Srinivas


DOI: 10.2174/157488411797189442




Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma

, 6(3): 189 - 198

Marc R. Matrana, Bradley Atkinson, Eric Jonasch and Nizar M. Tannir


DOI: 10.2174/157488411797189398




Looking Beyond Inhibition of VEGF/mTOR: Emerging Targets for Renal Cell Carcinoma Drug Development

, 6(3): 199 - 206

Neal Rasmussen and W. Kimryn Rathmell


DOI: 10.2174/157488411797189389




Immunotherapy and Targeted Therapy Combinations in Renal Cancer

, 6(3): 207 - 213

David F. McDermott


DOI: 10.2174/157488411797189451




Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

, 6(3): 214 - 221

Holleh D. Husseinzadeh and Jorge A. Garcia


DOI: 10.2174/157488411797189433




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science